trial

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

NCTId NCT03874494
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 371 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2021-08-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
371 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2019-11-27
Primary completion
2021-08-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Hongyan Zhang, PhDPrincipal Investigator

Sites

1 total
Xi’an, China

Linked catalysts

1
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia — primary completion2021-08-06

Facts & assertions

4 sourced
Enrollment
371
Phase
PHASE3
Primary Completion Date
2021-08-06
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Hongyan Zhang, PhD
person